Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-12-01 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (24 November 2025 to 28 November 2025). It includes detailed tables of daily aggregated volumes and individual transaction records, which is the standard format for 'Transaction in Own Shares' filings under market abuse regulations (MAR).
2025-12-01 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) for Sanofi. It provides a detailed breakdown of share buyback activities, including daily aggregated volumes and transaction-by-transaction details (date, time, price, quantity, and market). This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-12-01 English
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing the European Commission's approval of their drug, Dupixent, for a new indication (chronic spontaneous urticaria). It details the clinical study results, the regulatory approval, and provides contact information for media and investor relations. This is a standard corporate announcement regarding product development and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific financial reporting or governance categories.
2025-11-25 English
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing the European Commission's approval of their drug 'Dupixent' for the treatment of chronic spontaneous urticaria (CSU). It details the clinical study results (LIBERTY-CUPID program), the drug's mechanism, and provides corporate background for both companies. As this is a standard corporate announcement regarding product regulatory approval and clinical trial outcomes, it falls under the category of a general regulatory filing or corporate announcement.
2025-11-25 French
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding 'transactions sur actions propres' (transactions in own shares), specifically detailing share buybacks conducted between November 17, 2025, and November 21, 2025. It includes aggregated daily data and a granular transaction-by-transaction log, which is standard for share repurchase reporting under market abuse regulations (MAR). This aligns perfectly with the 'Transaction in Own Shares' (POS) category.
2025-11-24 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (17 November 2025 to 21 November 2025). It includes detailed tables of daily volumes, weighted average prices, and individual transaction logs, which is characteristic of a 'Transaction in Own Shares' report. This aligns perfectly with the definition for the POS filing category.
2025-11-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.